Novel customizable and flexible single-use assembly solution
Hugh Purity New England's solution can utilize other vendors' components and can be implemented directly into any process.
Demand for single-use assembly solutions in the biopharma industry continues to increase, with the market expected to be worth $26.89 billion by 2025.
To help meet that demand, High Purity New England (HPNE), a supplier of biopharma equipment and process solutions for the biopharma industry, has created HPConnexx, a single-use assembly solution suitable for all areas of biopharmaceutical processing from discovery to fill-finish.
Manufactured in an ISO 7 Cleanroom, the solution can utilize other vendors' components and can be implemented directly into any process.
“The solution, and the support we deliver around it, is truly unique as it can be customized in any way the customer requires. It can be connected to any existing process at any scale and utilize any components regardless of inter-company connectivity," explained the company's CEO and founder, Mark Sitcoske.
There is no minimum order size for an assembly and lead times can be as short as weeks, compared with the industry standard of months.
The team at HPNE also provide full integrity and validation testing on its single-use assemblies.
Sitcoske added: “Single-use technologies can reduce the costs associated with infrastructure, save time by decreasing the need for cleaning and validation and negate the risk of cross contamination. However, not all single-use solutions are fully customizable, and many have lengthy lead times for installation. That is why we developed HPConnexx.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...